CERNER AND ZEG BERLIN RAISE AWARENESS TO ACCELERATE THE UNDERSTANDING OF ENDOMETRIOSIS, ADENOMYOSIS AND MYOMA
Overland Park, KS — Jan. 24, 2022 — Cerner Corporation (NASDAQ: CERN), a global healthcare technology company, and ZEG Berlin announce their intention to launch the LIDEAM Registry: Long-term International Dual-Source Endometriosis, Adenomyosis and Myoma Registry. This is led by the new Cerner EnvizaSM operating unit that offers data-driven solutions and expertise that helps bring remarkable clarity to life sciences’ and healthcare’s most important decisions. The new registry will help increase awareness and knowledge of these diseases, accelerate earlier diagnosis and improve disease management.
Millions of people worldwide experience debilitating pelvic pain and abnormal bleeding associated with chronic gynecological conditions. Complex symptom profiles, like the final diagnosis of endometriosis, adenomyosis and myoma (uterine fibroids), often lead to long diagnostic delays.
Endometriosis, adenomyosis and myoma are characterized by a diverse set of symptoms including pelvic pain, heavy menstrual bleeding, pain during sexual intercourse and infertility. Additionally, these diseases have a significant negative impact on people’s quality of life including their physical, social and or mental well-being.
“We are enthusiastic about this opportunity to help make a difference for people and improve patient outcomes,” said Michael Fronstin, Global Head of Clinical Research and Consulting, Cerner Enviza. “We welcome life sciences organizations to contact us to learn more or to join our governance board.”
LIDEAM is an international registry focused on people experiencing symptoms suggestive of the three most common chronic gynaecological diseases and those with a recent diagnosis. LIDEAM will collect patient reported and clinical data with the intention of deepening the understanding of the real-world impact from a patient and caregiver perspective.
“The unmet needs and burden for people suffering from these diseases is significant,” said Clare Barnett, chief operating officer, ZEG Berlin. “Launching a global registry will enable us to better understand these diseases, to increase awareness and to improve patient care.”
Cerner EnvizaSM aims to accelerate the discovery, development and delivery of extraordinary insights and therapies to improve everyday health for all people globally. By combining decades of innovation, life sciences knowledge and collaborative research, Cerner Enviza provides data-driven solutions and expertise that helps bring remarkable clarity to life sciences’ and healthcare’s most important decisions. For more information, visit www.cernerenviza.com.
Cerner’s health technologies connect people and information systems at thousands of contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers a connected clinical and financial ecosystem to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit Cerner.com, Cerner Perspectives, connect on Facebook, Instagram, LinkedIn, Twitter or join the discussion on Cerner’s podcast Perspectives on Health & Tech. Nasdaq: CERN. Healthcare is too important to stay the same.
About ZEG Berlin
ZEG Berlin is a private research institute specialized in conducting non-interventional studies using real-world data. From protocol development to the final publication of study results, we believe in entering a collaborative partnership with our clients, striving to develop study designs that are best equipped to deliver quality data that accurately answers the question at hand. Our highly skilled team of epidemiologists, statisticians and data managers are passionate about harnessing the latest pharmacoepidemiology and technical developments to deliver regulatory-grade, real-world evidence studies. ZEG Berlin is a joint venture with Cerner. For more information visit www.zeg-berlin.de
Stephanie Greenwood, email@example.com